

IMPORTANT NEWS

Patients using **dolutegravir, elvitegravir/cobicistat** can be included. The amendment has been approved in all participating countries. We are considering to study cobicistat in combination with PIs, the decision is still pending.

Angela will defend her thesis in Nijmegen on **October 30th** at 14:30h. A PANNA investigator meeting/lunch will be organised on October 30th from appr. 11:00-13:30. Personal invitations will be sent out soon.

List of compounds under investigation, open now

panna

- Dolutegravir, Tivicay/Triumeq, DTG
- Elvitegravir, Vitekta, Stribild, EVG
- Cobicistat, Tibost, Stribild, COBI
- Etravirine, Intelence, ETV
- Rilpivirine, Edurant, Eviplera
- Efavirenz, Stocrin, Atripla, EFV*
- Fosamprenavir, Telzir, FPV
- Tipranavir, Aptivus, TPV
- Indinavir, Crixivan, IDV
- Enfuvirtide, Fuzeon, T-20


*UK/Ireland only

Closed arms:


Tenofovir, emtricitabine, atazanavir, darunavir, raltegravir, abacavir, maraviroc.

As we only need one inclusion in the efavirenz arm, please contact Angela or Stein prior to inclusion of a new patient.

Inclusions



Green: open arms orange: closed



PUBLICATIONS AND PRESENTATIONS

The raltegravir AND maraviroc papers have been accepted by CID.

Five posters have been presented at the HIV HCV pharmacology workshop in Washington DC: abacavir, rilpivirine, ritonavir, pop-PK darunavir and dolutegravir placenta passage (ex-vivo system).

We are working on a manuscript on abacavir and a joint manuscript (with IMPAACT) on etravirine. The efavirenz paper will follow soon.

Furthermore we are preparing abstracts for CROI: efavirenz and rilpivirine.

Have a nice holiday season and hope to see some of you on October 30th!



Angela, Stein and

David

Angela Colbers
Project manager
E-mail: Angela.Colbers@radboudumc.nl

Stein Schalkwijk
E-mail:
Stein.J.Schalkwijk@radboudumc.nl

Radboud university medical center,
Internal postal code 864, Department of
Pharmacy,
P.O. Box 9101, 6500 HB Nijmegen
Phone: + 31 (0)24 - 361 64 05